Inventiva (NASDAQ:IVA) Stock Rating Reaffirmed by HC Wainwright

Inventiva (NASDAQ:IVAGet Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $22.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 482.01% from the stock’s current price.

A number of other equities research analysts have also issued reports on the company. Lifesci Capital reaffirmed an “outperform” rating on shares of Inventiva in a research report on Friday, January 5th. Stifel Nicolaus cut their target price on Inventiva from $27.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $15.67.

Check Out Our Latest Analysis on IVA

Inventiva Price Performance

IVA opened at $3.78 on Wednesday. Inventiva has a one year low of $2.22 and a one year high of $5.05. The stock’s fifty day moving average is $3.78 and its 200-day moving average is $3.98.

Institutional Trading of Inventiva

Several institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC boosted its stake in shares of Inventiva by 20.5% during the 3rd quarter. Commonwealth Equity Services LLC now owns 24,435 shares of the company’s stock valued at $103,000 after buying an additional 4,155 shares during the period. Citigroup Inc. boosted its position in Inventiva by 91.7% during the first quarter. Citigroup Inc. now owns 23,000 shares of the company’s stock valued at $84,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Morgan Stanley grew its stake in Inventiva by 300.0% in the fourth quarter. Morgan Stanley now owns 6,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,500 shares in the last quarter. 11.46% of the stock is currently owned by institutional investors and hedge funds.

Inventiva Company Profile

(Get Free Report)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.

Recommended Stories

Analyst Recommendations for Inventiva (NASDAQ:IVA)

Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with's FREE daily email newsletter.